-transparent.png){kind=logo}
Current opinions concerning tumor biology and clinical characteristics of small cell undifferentiated bronchogenic carcinoma are reviewed. Special emphasis is placed upon chemotherapy for this lung cancer subtype and presently achievable response rates and survival times are presented. A series of 16 patients with small cell undifferentiated bronchogenic carcinoma is also presented. All patients were given cyclophosphamide, methotrexate, vincristine, and procarbazine as treatment for this neoplasm. Sixty-eight percent of patients responded and the survival time in partial responders was 33.4+ weeks as compared to 13.7 weeks with nonresponders. These data correlate well with the previous data of Alberto et al [Alberto P, Brunner KW, Martz G, Obrect JP: Cancer 38:2208--2216, 1976], who investigated the same agents for this tumor, but at higher dosages.
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
May 1978,
Southern medical journal,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
April 1998,
Archivos de bronconeumologia,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
January 1977,
Cancer treatment reports,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
February 1983,
Onkologie,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
March 1984,
L'union medicale du Canada,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
March 1983,
Seminars in oncology,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
August 1980,
International journal of radiation oncology, biology, physics,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
March 1984,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
June 1977,
JAMA,
P S Johnson, and
J F Foley, and
A Kessinger, and
H M Lemon
February 1979,
Cancer treatment reports,
